Search - tctmd.com

Displaying 81 - 100 of 1590

Sort: Relevancy | Date

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Michael O'Riordan

May 02, 2025

News Daily News

Access to GLP-1 Drugs Unequal for US Patients With Obesity

Caitlin E. Cox

May 01, 2025

News Daily News

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Yael L. Maxwell

April 29, 2025

News Conference News HRS 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Todd Neale

April 28, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News EHRA 2025

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

Todd Neale

April 01, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Advertisement

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Access to GLP-1 Drugs Unequal for US Patients With Obesity

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

GLP-1 Drugs May Have Role in Secondary Prevention of AF

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

April 2025 Dispatch for the CV Team

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Cardiotoxicity Rare With Common GI Chemotherapy

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Sudden Cardiac Death Risk Linked to Long-term Antidepressant Use

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content